PortfoliosLab logoPortfoliosLab logo
XERS vs. UAMY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

XERS vs. UAMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Xeris Biopharma Holdings, Inc. (XERS) and United States Antimony Corporation (UAMY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, XERS achieves a 2.93% return, which is significantly higher than UAMY's 1.00% return.


XERS

1D
-4.04%
1M
-2.42%
6M
9.78%
YTD
2.93%
1Y
50.19%
3Y*
44.28%
5Y*
21.35%
10Y*
ALL TIME*
-7.90%

UAMY

1D
-2.87%
1M
-31.76%
6M
-30.83%
YTD
1.00%
1Y
71.28%
3Y*
129.58%
5Y*
39.11%
10Y*
33.59%
ALL TIME*
6.99%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$26.13M$31.95M$72.73M
$11.42M$15.11M$13.85M

XERS vs. UAMY - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
XERS
Xeris Biopharma Holdings, Inc.
2.93%131.56%44.26%76.69%-54.61%-40.45%-30.21%-58.53%7.94%
UAMY
United States Antimony Corporation
1.00%183.62%610.84%-48.86%-2.19%-4.64%35.58%-33.62%12.62%

Correlation

The correlation between XERS and UAMY is 0.03, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.03

Correlation (3Y)
Balances recent behavior with more history.

0.12

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.15

Correlation (All Time)
Calculated using the full available price history since Jun 21, 2018

0.12

The correlation between XERS and UAMY shifts across timeframes, from 0.03 (1 year) to 0.15 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

XERS:

$1.39B

UAMY:

$751.30M

EPS

XERS:

$0.07

UAMY:

-$0.12

PS Ratio

XERS:

4.58

UAMY:

16.82

PB Ratio

XERS:

110.31

UAMY:

5.44

Total Revenue (TTM)

XERS:

$314.85M

UAMY:

$39.04M

Gross Profit (TTM)

XERS:

$187.04M

UAMY:

$4.34M

EBITDA (TTM)

XERS:

$41.72M

UAMY:

-$15.23M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

XERS vs. UAMY — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

XERS
XERS Risk / Return Rank: 7373
Overall Rank
XERS Sharpe Ratio Rank: 7777
Sharpe Ratio Rank
XERS Sortino Ratio Rank: 7474
Sortino Ratio Rank
XERS Omega Ratio Rank: 7676
Omega Ratio Rank
XERS Calmar Ratio Rank: 7171
Calmar Ratio Rank
XERS Martin Ratio Rank: 6666
Martin Ratio Rank

UAMY
UAMY Risk / Return Rank: 6666
Overall Rank
UAMY Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
UAMY Sortino Ratio Rank: 7474
Sortino Ratio Rank
UAMY Omega Ratio Rank: 6868
Omega Ratio Rank
UAMY Calmar Ratio Rank: 6464
Calmar Ratio Rank
UAMY Martin Ratio Rank: 6060
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

XERS vs. UAMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Xeris Biopharma Holdings, Inc. (XERS) and United States Antimony Corporation (UAMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


XERSUAMYDifference
Sharpe ratioReturn per unit of total volatility

+0.56

Sortino ratioReturn per unit of downside risk

+0.01

Omega ratioGain probability vs. loss probability

1.23

1.18

+0.05

Calmar ratioReturn relative to maximum drawdown

1.27

0.89

+0.38

Martin ratioReturn relative to average drawdown

2.17

1.36

+0.81

XERS vs. UAMY - Sharpe Ratio Comparison

The current XERS Sharpe Ratio is 1.07, which is higher than the UAMY Sharpe Ratio of 0.51. The chart below compares the historical Sharpe Ratios of XERS and UAMY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

XERS vs. UAMY - Drawdown Comparison

The maximum XERS drawdown since its inception was -96.22%, roughly equal to the maximum UAMY drawdown of -96.44%. Use the drawdown chart below to compare losses from any high point for XERS and UAMY.


Loading charts...

Drawdown Indicators


XERSUAMYDifference

Max Drawdown

Largest peak-to-trough decline

-96.22%

-96.44%

+0.22%

Max Drawdown (1Y)

Largest decline over 1 year

-46.57%

-74.30%

+27.73%

Max Drawdown (3Y)

Largest decline over 3 years

-47.20%

-74.30%

+27.10%

Max Drawdown (5Y)

Largest decline over 5 years

-64.85%

-80.46%

+15.61%

Max Drawdown (10Y)

Largest decline over 10 years

-89.76%

Current Drawdown

Current decline from peak

-70.33%

-70.98%

+0.65%

Average Drawdown

Average peak-to-trough decline

-78.86%

-66.39%

-12.47%

Ulcer Index

Depth and duration of drawdowns from previous peaks

27.13%

48.56%

-21.43%

Volatility

XERS vs. UAMY - Volatility Comparison

The current volatility for Xeris Biopharma Holdings, Inc. (XERS) is 13.14%, while United States Antimony Corporation (UAMY) has a volatility of 24.68%. This indicates that XERS experiences smaller price fluctuations and is considered to be less risky than UAMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


XERSUAMYDifference

Volatility (1M)

Calculated over the trailing 1-month period

13.14%

24.68%

-11.54%

Volatility (6M)

Calculated over the trailing 6-month period

30.94%

83.69%

-52.75%

Volatility (1Y)

Calculated over the trailing 1-year period

55.25%

130.50%

-75.25%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

67.85%

95.37%

-27.52%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

79.23%

101.21%

-21.98%

Dividends

XERS vs. UAMY - Dividend Comparison

Neither XERS nor UAMY has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

XERS vs. UAMY - Financials Comparison

This section allows you to compare key financial metrics between Xeris Biopharma Holdings, Inc. and United States Antimony Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


XERS and UAMY have a correlation of 0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

UAMY has higher volatility (24.68%) compared to XERS (13.14%). In terms of maximum drawdown, XERS dropped -96.22% vs UAMY's -96.44%.

XERS currently has the higher Sharpe Ratio (1.07 vs 0.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for XERS and UAMY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer